Category: DEA

It Is Time To Deschedule, Not Reschedule, Cannabis

A recent memorandum from the US Drug Enforcement Administration to several United States Senators indicates that the agency is prepared to respond in the coming months to a five-year-old petition seeking to amend the plant’s status as a schedule I prohibited substance. Under the US Controlled Substances Act of 1970, the cannabis plant and its organic cannabinoids are classified as schedule I prohibited substances — the most restrictive category available under the law. As summarized by the DEA, “Schedule I drugs are the most dangerous drugs of all the drug schedules with potentially severe psychological or physical dependence.” Explicitly, substances in this category must meet three specific inclusion criteria: The substance must possess “a high potential for abuse”; it must…

Read More

NIDA Acknowledges Drawbacks to Monopoly on Marijuana Supply

Members of the US Senate at a hearing yesterday expressed skepticism in regard to federal policies limiting the ability of investigators to engage in clinical studies of marijuana’s health benefits. Senators heard from representatives from the Drug Enforcement Administration (DEA), Food and Drug Administration (FDA), National Institute on Drug Abuse (NIDA), University of Mississippi Medical Center, Arrowhead Regional Medical Center and Project SAM on a variety of issues The hearing’s most noteworthy moment came when Nora Volkow, director of NIDA, acknowledged that the monopoly on marijuana cultivation for research purposes […]